Product category:
Chemicals and biochemicals
News Release from: PolyTherics
Edited by the Laboratorytalk Editorial
Team on 14 August 2007
PolyTherics and BioVectra sign
manufacturing deal
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy has signed a manufacturing and bilateral representation agreement with BioVectra
A Canadian biopharmaceutical company, BioVectra, supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry The agreement, which follows hard on the heels of PolyTherics' recent successful fundraising of over GBP2 million, will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients' clinical development of PolyTherics' novel PEGylation technology
This article was originally published on Laboratorytalk on 6 Dec 2001 at 8.00am (UK)
Related stories
Akcros invests in solid stabilisers
To meet growing demand for PVC stabilisers, Akcros Chemicals will invest in increased production of the Interlite ZP range of solid mixed metal soap stabilisers at its Eccles, UK, facility
MBO for Akcros
Akzo Nobel plastics and processing additives business unit, making lead stabilisers for polymer products sold, to management, and to trade under the new name Allstab
BioVectra will also market the PEGylation technology to its client base in North America.
PolyTherics has developed patent-protected proprietary technologies and expertise in the modification of drugs to improve their performance.
The company's innovative PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs.
Further reading
Purpose-built state-of-the-art facilities
New facilities operate to the latest ISO 2000/ PS 9100 standards and include new laboratories where product testing is conducted according to industry and customer specifications
Folic acid kit meets with approval
Food manufacturers worldwide now have a trusted and effective routine means to rapidly meet legal requirements on vitamin fortification
Agent covers US territory
Organoboron compound manufacturer Boron Molecular expands into the USA with the recruitment of an exclusive agent
The TheraPEG approach produces an improvement in biological activity and a higher yield than the existing PEGylation technologies.
This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses.
Patients can therefore be treated less often, with fewer side-effects and at lower cost.
The market for traditional PEGylation has expanded considerably and PolyTherics' TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field.
PolyTherics already has revenue-generating development contracts in place with several companies and is in discussion with a number of other parties.
Dr Keith Powell, chief executive officer of PolyTherics, said: "We are delighted to have signed this agreement with BioVectra, who offer access to specialist custom polymer chemistry capabilities, a patented MPEG purification process and scaled manufacturing systems - the key components that are needed to support clients of our TheraPEG technology.
"We are currently in discussion with a number of biogeneric and pharmaceutical companies in Europe and the USA and there is significant interest in downstream applications for our TheraPEG technology.
"This agreement with BioVectra means that we can work with a highly competent manufacturer who will supply the highest quality MPEGs to meet our clients' needs and comply with FDA standards.
"So we now have the tools to take our TheraPEG technology from the laboratory into the feasibility testing and manufacturing stages".
Stephen Ball, business development representative for BioVectra, said: "We are pleased to be working with PolyTherics to support the development of their innovative and important site specific TheraPEG technology.
"We look forward to deploying our capabilities in the manufacturing of high quality cGMP MPEG reagents to assist PolyTherics' clients through clinical development of therapeutic proteins into post approval commercialisation".
Dale Zajicek, chief operating officer of BioVectra, said: "We remain committed to supporting our PEGs business initiatives with technology that creates true value for our customers and their patients.
"The PolyTherics agreement is a clear example of this commitment.".
• PolyTherics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
